A 42-year-old woman undergoing chemotherapy with cisplatin for ovarian cancer develops severe nausea and vomiting on day 1 of treatment despite receiving ondansetron 8 mg IV 30 minutes before chemotherapy. She vomits 6 times in the first 4 hours post-chemotherapy. What is the most appropriate next step in management?

Explanation

## Management of Chemotherapy-Induced Nausea and Vomiting (CINV) ### Clinical Context Cisplatin is a **highly emetogenic chemotherapy agent** (risk >90%). Breakthrough emesis despite adequate 5-HT₃ antagonist dosing requires escalation of the antiemetic regimen, not monotherapy adjustment. ### Rationale for Correct Answer **Key Point:** Highly emetogenic chemotherapy (HEC) requires **multimodal antiemetic prophylaxis** combining: 1. 5-HT₃ antagonist (ondansetron) 2. **Corticosteroid (dexamethasone)** — synergistic effect 3. **NK₁ receptor antagonist (aprepitant)** — for HEC, especially cisplatin **High-Yield:** The standard regimen for cisplatin-induced CINV includes: - Ondansetron 8 mg IV before chemotherapy - **Dexamethasone 8 mg IV/PO daily × 2–4 days** (potentiates 5-HT₃ blockade) - **Aprepitant 125 mg PO day 1, then 80 mg days 2–3** (blocks substance P/neurokinin-1 pathway — independent mechanism from 5-HT₃ antagonists) This triple-drug combination reduces CINV incidence to ~70–80% in HEC patients. ### Why Monotherapy Escalation Fails | Agent | Mechanism | Limitation in HEC | |-------|-----------|-------------------| | 5-HT₃ antagonist alone | Blocks serotonin at chemoreceptor trigger zone | Incomplete; substance P and other pathways active | | Corticosteroid alone | Reduces inflammatory mediators; enhances 5-HT₃ effect | Synergistic only when combined | | NK₁ antagonist alone | Blocks neurokinin-1 pathway | Delayed emesis control; works best with 5-HT₃ antagonist | **Clinical Pearl:** Dexamethasone is particularly effective for **delayed emesis** (>24 hours post-chemotherapy), which is common with cisplatin. Aprepitant covers both acute and delayed phases. ### Timing and Premedication Protocol ```mermaid flowchart TD A[Highly Emetogenic Chemotherapy<br/>e.g., Cisplatin]:::outcome --> B[Day 0: Pre-chemotherapy]:::action B --> C["Ondansetron 8 mg IV<br/>+ Dexamethasone 8 mg IV<br/>+ Aprepitant 125 mg PO"]:::action C --> D[Administer chemotherapy]:::action D --> E[Days 1-3: Continuation]:::action E --> F["Dexamethasone 8 mg daily<br/>+ Aprepitant 80 mg days 2-3<br/>+ Ondansetron PRN"]:::action F --> G[Assess response]:::decision G -->|Controlled| H[Continue current regimen]:::outcome G -->|Breakthrough emesis| I[Add lorazepam or olanzapine]:::action ``` **Mnemonic:** **HEC-DANK** — Highly Emetogenic Chemotherapy needs **D**examethasone, **A**ntagonist (5-HT₃), **N**K₁ antagonist (aprepitant), **K**eep monitoring. [cite:KD Tripathi 8e Ch 16]